This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
by Ahan Chakraborty
IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.
IONSNegative Net Change KODNegative Net Change MNPRPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up
by Zacks Equity Research
CYTK enters a new era as FDA approval of Myqorzo transforms it into a commercial biotech, opening a long-term growth runway in cardiology.
BMYNegative Net Change FOLDNegative Net Change CYTKNegative Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
by Sundeep Ganoria
Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
GSKPositive Net Change BMYNegative Net Change MRKNegative Net Change AMGNNegative Net Change GILDNegative Net Change
biotechs medical pharmaceuticals
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026
by Ekta Bagri
EyePoint, ANI Pharmaceuticals and Tango Therapeutics put up a stellar show in 2025 and are set to carry the momentum in 2026 as well.
ANIPNegative Net Change EYPTNegative Net Change TNGXNegative Net Change
biotechnology biotechs medical pharmaceuticals
MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab
by Zacks Equity Research
Moderna secures up to $54.3 million from CEPI to fund a pivotal phase III study of its mRNA-based H5 pandemic flu vaccine candidate, mRNA-1018.
MRNANegative Net Change ANIPNegative Net Change CRMDPositive Net Change CSTLPositive Net Change
biotechs
Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema
by Zacks Equity Research
NVO files an NDA with the FDA for once-weekly CagriSema, a combo obesity injection showing superior weight loss in obese patients in phase III studies.
NVONegative Net Change LLYNegative Net Change CRMDPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will GILD's Strong HIV Portfolio Reap Rewards in 2026?
by Ekta Bagri
GILD???s HIV franchise gains momentum as twice-yearly PrEP Yeztugo wins FDA approval and late-stage data back a new single-tablet regimen.
GSKPositive Net Change MRKNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant
by Zacks Equity Research
JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.
AZNPositive Net Change JNJNegative Net Change HALONegative Net Change
biotechs medical pharmaceuticals
SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug Tag
by Zacks Equity Research
Sanofi gains EMA Orphan Drug status for efdoralprin alfa, a phase II biologic for AATD-related emphysema with promising dosing data.
SNYPositive Net Change ANIPNegative Net Change CRMDPositive Net Change CSTLPositive Net Change
biotechs medical
Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026?
by Zacks Equity Research
Mirum's Livmarli sales surge 70% in the first nine months of 2025. Expanding approvals and commercialization are set to fuel revenue momentum into 2026.
GSKPositive Net Change MIRMNegative Net Change TVTXNegative Net Change
biotechs
Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share?
by Ahan Chakraborty
NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S. momentum.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi
by Zacks Equity Research
INCY wins EC approval expanding Minjuvi's label, adding a new indication for relapsed or refractory follicular lymphoma after prior therapy.
NVSNegative Net Change QGENNegative Net Change INCYNegative Net Change
biotechnology biotechs medical pharmaceuticals
PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study
by Zacks Equity Research
Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer.
RHHBYPositive Net Change CRMDPositive Net Change PCSANegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset
by Zacks Equity Research
Insmed sinks nearly 20% after Brinsupri failed a phase IIb sinus study, while the company adds a new monoclonal antibody asset to expand its pipeline.
INSMNegative Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechs medical
5 Biotech Stocks to Watch for Potential Upside
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector.
ARQTNegative Net Change FOLDNegative Net Change PCRXNegative Net Change ANIPNegative Net Change TNGXNegative Net Change
biotechnology biotechs medical pharmaceuticals
CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy?
by Kanishka Das
CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.
PFENegative Net Change PBYINegative Net Change CRMDPositive Net Change
biotechs
GSK's Exdensur Gets FDA Nod for Severe Asthma Treatment
by Zacks Equity Research
GSK secures FDA approval for Exdensur, the first twice-yearly biologic for treating severe asthma with an eosinophilic phenotype.
GSKPositive Net Change ANIPNegative Net Change CRMDPositive Net Change CSTLPositive Net Change
biotechs
Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?
by Sundeep Ganoria
PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.
PFENegative Net Change NVONegative Net Change LLYNegative Net Change SMMTNegative Net Change
biotechs medical pharmaceuticals vaccines
RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know
by Zacks Equity Research
Rezolute shares collapse 79% so far in December after a phase III hyperinsulinism study of its only pipeline candidate miss primary and key secondary endpoints.
ANIPNegative Net Change CRMDPositive Net Change RZLTNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer
by Zacks Equity Research
AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer.
AZNPositive Net Change ANIPNegative Net Change CRMDPositive Net Change CSTLPositive Net Change
biotechs
SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
by Zacks Equity Research
Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib, and a phase III study fails to hit its primary endpoint.
SNYPositive Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechs medical pharmaceuticals
FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock?
by Zacks Equity Research
Amicus hits a 52-week high after an 87.6% six-month surge, driven by strong Galafold sales and rising uptake of Pombiliti + Opfolda.
SNYPositive Net Change TEVANegative Net Change FOLDNegative Net Change
biotechs
KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data
by Zacks Equity Research
Kyverna Therapeutics shares jump 23% after a registrational phase II study of miv-cel meets primary and all secondary efficacy goals for treating stiff person syndrome.
ANIPNegative Net Change CRMDPositive Net Change CSTLPositive Net Change KYTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike
by Zacks Equity Research
CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.
MRNANegative Net Change ANIPNegative Net Change CRMDPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals vaccines
How AbbVie's Pipeline Is Lining Up Key Product Launches
by Sundeep Ganoria
ABBV is lining up multiple late-stage launches, from Rinvoq label expansions to Parkinson???s and oncology assets nearing FDA decisions.
JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals